{
  "guideline": {
    "id": "PA166279721",
    "name": "Annotation of CPIC Guideline for nitrofurantoin and G6PD",
    "objCls": "Guideline Annotation",
    "source": "CPIC",
    "version": 1,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166279721",
    "relatedChemicals": [
      {
        "id": "PA450640",
        "name": "nitrofurantoin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA28469",
        "name": "glucose-6-phosphate dehydrogenase",
        "symbol": "G6PD"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166298246",
      "name": "Recommendation PA166298246",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450640",
          "name": "nitrofurantoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060848,
        "html": "<p>Avoid</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype to rate as &quot;strong,&quot; but all medium risk drugs should be avoided in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.</p>\n"
      },
      "implications": [
        "G6PD: High risk of acute of acute exacerbation of chronic hemolysis"
      ],
      "lookupKey": {
        "G6PD": "Deficient with CNSHA"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298245",
      "name": "Recommendation PA166298245",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA450640",
          "name": "nitrofurantoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060847,
        "html": "<p>Use at standard doses with caution and with close monitoring for anemia</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Close monitoring may be more important at higher or more chronic dosage schedules, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.</p>\n"
      },
      "implications": [
        "G6PD: Medium risk of acute hemolytic anemia"
      ],
      "lookupKey": {
        "G6PD": "Deficient"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298247",
      "name": "Recommendation PA166298247",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450640",
          "name": "nitrofurantoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060849,
        "html": "<p>If deemed necessary to ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class Iâ€“III) allele may display a normal or a deficient phenotype; an enzyme activity test is needed to assign G6PD phenotype in such cases.</p>\n"
      },
      "implications": [
        "G6PD: Variable risk of acute hemolytic anemia"
      ],
      "lookupKey": {
        "G6PD": "Variable"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298248",
      "name": "Recommendation PA166298248",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA450640",
          "name": "nitrofurantoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060850,
        "html": "<p>To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.</p>\n"
      },
      "implications": [
        "G6PD: Unknown risk of acute hemolytic anemia"
      ],
      "lookupKey": {
        "G6PD": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298244",
      "name": "Recommendation PA166298244",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA450640",
          "name": "nitrofurantoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060846,
        "html": "<p>No reason to avoid based on G6PD status</p>\n"
      },
      "implications": [
        "G6PD: Low risk of acute hemolytic anemia"
      ],
      "lookupKey": {
        "G6PD": "Normal"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [],
  "version": "2024-03-08-14-34"
}